TCRXNGMHealthcare·Biotechnology#405 in industry

TScan Therapeutics, Inc.

+17.9% · 90d

$1.32

+0.06 (+4.76%)

News

(1)

April 2026

Apr 7, 20262 weeks agoPRE 14AHealthcare

TScan Therapeutics Seeks Shareholder Approval to Double Authorized Shares

TCRXTScan Therapeutics, Inc.

# 🧾 What This Document Is This is a **PRE 14A**, also known as a preliminary proxy statement. Think of it as the official "voter's guide" for TScan Therapeutics' upcoming annual shareholder meeting. The company is required to file this with the SEC to provide shareholders with all the information t

Read summaryView on SEC EDGAR

Key Data

Market Cap$79.3M

Open$1.25

Prev Close$1.26

Day Range$1.22 – $1.35

52W Range$0.88 – $2.57

Volume763,285

P/E (TTM)—

EPS$-1.00

Dividend Yield—

Beta1.01

Revenue Growth286.00%

Price Target$6.00(+354.5%)

Analyst Ratings

Strong Buy6 analysts

Buy 5Hold 1Sell 0

About

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Healthcare · Biotechnology

142 employees

www.tscan.com